Should pregnant women be screened for SARS-CoV-2 infection? A prospective multicenter cohort study.
COVID-19
SARS-CoV-2
pregnancy
screening
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
revised:
26
06
2022
received:
26
02
2022
accepted:
08
07
2022
pubmed:
17
7
2022
medline:
16
12
2022
entrez:
16
7
2022
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranges from asymptomatic to severe infection. We aimed to compare the prevalence of COVID-19 in asymptomatic pregnant versus nonpregnant women in order to establish recommendations for a COVID-19 screening strategy. A prospective multicenter cohort study was conducted. Asymptomatic pregnant or nonpregnant women after March 2020 (the time when COVID-19 was first detected in north Israel) were tested for SARS-CoV-2 using nasopharyngeal reverse transcription polymerase chain reaction test, anti-nucleocapsid IgG, and anti-spike IgG. Diagnosis was made if at least one test result was positive. Pregnant women were tested between 34 and 42 weeks, mostly at birth. Among the 297 participating women, 152 were pregnant and 145 were nonpregnant. The prevalence of asymptomatic COVID-19 was similar between the groups (4 [2.6%] and 8 [5.5%], respectively; P = 0.2). All women with COVID-19 delivered healthy appropriate-for-gestational-age babies without malformations, at term. The rate of asymptomatic COVID-19 in pregnant women is low and comparable to the rate among nonpregnant women. Pregnancy outcomes are favorable. Future screening programs should consider that one of 25 screened asymptomatic women will be positive.
Identifiants
pubmed: 35842225
doi: 10.1002/ijgo.14359
pmc: PMC9349848
doi:
Substances chimiques
Immunoglobulin G
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
161-166Informations de copyright
© 2022 International Federation of Gynecology and Obstetrics.
Références
Symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1641-1647.
Ellington S, Strid P, Tong VT, et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States, January 22-June 7, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:769-775.
Delahoy MJ, Whitaker M, O'Halloran A, et al. Characteristics and maternal and birth outcomes of hospitalized pregnant women with laboratory-confirmed COVID-19 - COVID-NET, 13 States, March 1-August 22, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1347-1354.
Woodworth KR, Olsen EO, Neelam V, et al. Birth and infant outcomes following laboratory-confirmed SARS-CoV-2 infection in pregnancy - SET-NET, 16 jurisdictions, March 29-October 14, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1635-1640.
Villar J, Ariff S, Gunier RB, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study. Am J JAMA Pediatr. 2021;175:817-826.
Rosenbloom JI, Raghuraman N, Carter EB, Kelly JC. Coronavirus disease 2019 infection and hypertensive disorders of pregnancy. Obstet Gynecol. 2021;224:623-624.
Roberts DJ, Edlow AG, Romero RJ, et al. SPECIAL REPORT: a standardized definition of placental infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a consensus statement from the National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development (NIH/NICHD) SARS-CoV-2 placental infection workshop. Am J Obstet Gynecol. 2021;225(6):593.e1-593.e9.
Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9:386-389.
Dashraath P, Wong JLJ, Lim MXK, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol. 2020;222:521-531.
Mor G, Aldo P, Alvero AB. The unique immunological and microbial aspects of pregnancy. Nat Rev Immunol. 2017 Aug;17(8):469-482.
Varela AR, Florez LJH, Tamayo-Cabeza G, et al. Factors associated with SARS-CoV-2 infection in Bogota, Colombia: results from a large epidemiological surveillance study. Lancet Reg Health Am. 2021;2:100048.
Dawood FS, Varner M, Tita A, et al. Incidence, clinical characteristics, and risk factors of SARS-CoV-2 infection among pregnant individuals in the United States. Clin Infect Dis. 2021;74(12):2218-2226.
Häusler S, Weigl M, Ambrosch A, Gruber R, Seelbach-Göbel B, Fill MS. Peripartal anti-SARS-CoV-2-IgA/IgG in asymptomatic pregnant women during regional SARS-CoV-2-outbreak. J Perinat Med. 2021;49:709-716.
Savirón-Cornudella R, Villalba A, Esteban LM, et al. Screening of severe acute respiratory syndrome coronavirus-2 infection during labor and delivery using polymerase chain reaction and immunoglobulin testing. Life Sci. 2021;271:119200.
Savirón-Cornudella R, Villalba A, Zapardiel J, Andeyro-Garcia M, Esteban LM, Pérez-López FR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) universal screening in gravids during labor and delivery. Eur J Obstet Gynecol Reprod Biol. 2021;256:400-404.
Breslin N, Baptiste C, Gyamfi-Bannerman C, et al. Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. Am J Obstet Gynecol MFM. 2020;2(2):100118.
Khalil A, Hill R, Ladhani S, Pattisson K, O'Brien P. Severe acute respiratory syndrome coronavirus 2 in pregnancy: symptomatic pregnant women are only the tip of the iceberg. Am J Obstet Gynecol. 2020 Aug;223(2):296-297.
Hashim NAF, Mahdy ZA, Abdul Rahman R, Kalok AHM, Sutan R. Universal testing policy for COVID-19 in pregnancy: a systematic review. Front Public Health. 2022;10:588269.
Glennon K, Donnelly J, Knowles S, et al. Immunological assessment of SARS-CoV-2 infection in pregnancy from diagnosis to delivery: a multicentre prospective study. PLoS One. 2021 Sep 20;16(9):e0253090.
Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PloS Med. 2020;17:e1003346.
Havervall S, Ng H, Falk AJ, et al. Robust humoral and cellular immune responses and low risk for reinfection at least eight months following asymptomatic to mild COVID-19. J Intern Med; 2021.
Kaufman HW, Chen Z, Meyer WA 3rd, Wohlgemuth JG. Insights from patterns of SARS-CoV-2 immunoglobulin G serology test results from a National Clinical Laboratory, United States, March-July 2020. Popul Health Manag. 2021;24(S1):S35-S42.
Petersen LR, Sami S, Vuong N, et al. Lack of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a large cohort of previously infected persons. Clin Infect Dis. 2021;73(9):e3066-e3073.